Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Unknown 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Multiple Myeloma 6Recurrence 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Acute 4Breast Neoplasms 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Hodgkin Disease 2Hematologic Neoplasms 2Glioma 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Blast Crisis 2Thrombocytosis 1Stomach Neoplasms 1Somatostatinoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Rhabdoid Tumor 1

Interventions

Rituximab 66Cyclophosphamide 52fludarabine phosphate 26fludarabine 22Filgrastim 21Vincristine 19Methotrexate 19Melphalan 19Doxorubicin 18Radiotherapy 17Etoposide 17Prednisone 16Tacrolimus 15Whole-Body Irradiation 14Mycophenolic Acid 14Cytarabine 14Peripheral Blood Stem Cell Transplantation 13Gemcitabine 13Cyclosporine 13Antilymphocyte Serum 13Lenalidomide 12Busulfan 11Bortezomib 11Granulocyte Colony-Stimulating Factor 9Alemtuzumab 9sargramostim 8Dexamethasone 8Cord Blood Stem Cell Transplantation 8pembrolizumab 7ibritumomab tiuxetan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma × Panobinostat × Clear all
NCT01282476 2017-05-09

Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
18 enrolled 20 charts
LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡